-
-
-
-
-
-
-
BMO Capital Reiterates Market Perform Rating on BridgeBio Pharma (BBIO)
-
-
-
-
-
-
-
Evercore ISI on HELIOS-B Read-Through to BridgeBio Pharma (BBIO)
-
-
-
-
-
-
-
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
-
-
-
-
-
-
-
BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

